Tatva Chintan Pharma Chem Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4ifieblxvwb7rt0a2s43o8cx.pdf

Key Takeaways


Demand Environment & Segment Performance

Chintan Shah: "the chemical industry is definitely going through a never seen before situation and the pain is yet not completely over"

SDA: The Growth Engine for FY25

Chintan Shah: "We expect at least 80% to 100% growth in this segment in terms of value."

New Product Pipeline & Commercialization


Margins, Costs & Balance Sheet

Chintan Shah: "Honestly, I don't consider R&D expenses as an expense because without this, we are not going to grow ever. So, I would not say this is an expense. I would say this is practically an investment that we are making."

Strategic Initiatives

Chintan Shah: "This is coming because of adopting the concept of providing them a solution to have a security of supply by having a non-Chinese origin supply chain. This concept has paid off."

Guidance & Commitments

CommitmentSpecificsTimeline
FY24 revenue growthNearly flattish, maybe 5% to 7% growthFY24
FY24 EBITDAClose to about Rs. 100 croresFY24
FY25 revenue growthAt least 70% to 100% growthFY25
SDA segment growthAt least 80% to 100% growth in valueFY25
New SDA customer commercializationFirst volumes begin February 2024, ramp from July 2024Q4FY24 onward
Three agro intermediate commercializationsAll three between April and June of next yearQ1FY26
Three pharma intermediate commercializationsBy early 2025Early CY2025
Flame retardant production restartSlow commercial production begins for newly approved customerQ4FY24
Old inventory loss absorptionRs. 7–8 crores loss, in one quarter or spread over threeOver next 1–3 quarters
Capacity debottleneckingRs. 30–40 crores of expensesNext 6–8 months
Monoglyme plant-scale productionBegin within next 12 months~Q3FY25
Tax rate reductionDrastically down from 29–30% as depreciation is consumedPotentially FY25

Key Metrics

MetricQ2 FY24
Revenue from operations₹96.7 cr, +7% YoY
EBITDA₹20.2 cr, +81% YoY
EBITDA margin20.9%, up 849 bps YoY from 12.4%
PAT₹7.8 cr, +9% YoY
PAT margin8.05%, vs 7.89% in Q2 FY23
Gross profit margin61%, up sharply from ~50% range historically
FY24 revenue growth guidance5% to 7%, nearly flattish growth
FY24 EBITDA guidance~₹100 cr
FY25 revenue growth guidance70% to 100%
SDA quarterly revenue₹42.8 cr, +487% YoY
PTC quarterly revenue₹23.2 cr, -25% YoY
Pharma and Agro Intermediates and Specialty Chemicals quarterly revenue₹28.8 cr, -22% YoY
Electrolyte Salts quarterly revenue₹1.2 cr, -79% YoY
Exports₹67.1 cr, 69% of revenue from operations
Employee cost as % of revenue~15%, vs normal 6% to 8%
Headcount increase in H1 FY24116
Effective tax rate guidance FY2429% to 30%
CAPEX FY24~₹250 cr
QIP proceeds utilized₹184 cr of ₹200 cr, 95% utilized
IPO proceeds utilized₹202.7 cr of ₹207.28 cr, 98% utilized